{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:42:55Z","timestamp":1770504175073,"version":"3.49.0"},"reference-count":260,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Respiratory Medicine"],"published-print":{"date-parts":[[2015,9,3]]},"DOI":"10.1586\/17476348.2015.1081066","type":"journal-article","created":{"date-parts":[[2016,2,13]],"date-time":"2016-02-13T21:17:15Z","timestamp":1455398235000},"page":"633-654","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":44,"title":["Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies"],"prefix":"10.1586","volume":"9","author":[{"given":"Angela","family":"Bononi","sequence":"first","affiliation":[{"name":"University of Hawai\u2018i Cancer Center, University of Hawai\u2018i at M\u0101noa, Honolulu,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Napolitano","sequence":"additional","affiliation":[{"name":"University of Hawai\u2018i Cancer Center, University of Hawai\u2018i at M\u0101noa, Honolulu,","place":["USA"]},{"name":"Molecular Biosciences and Bioengineering, University of Hawai\u2018i at M\u0101noa, Honolulu,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey I","family":"Pass","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, Division of Thoracic Surgery, Langone Medical Center, New York University,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haining","family":"Yang","sequence":"additional","affiliation":[{"name":"University of Hawai\u2018i Cancer Center, University of Hawai\u2018i at M\u0101noa, Honolulu,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Carbone","sequence":"additional","affiliation":[{"name":"University of Hawai\u2018i Cancer Center, University of Hawai\u2018i at M\u0101noa, Honolulu,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,8,25]]},"reference":[{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22724"},{"key":"e_1_3_3_6_1","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner JC","year":"1960","unstructured":"Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960;17:260-71","journal-title":"Br J Ind Med"},{"issue":"5","key":"e_1_3_3_7_1","first-page":"409","article-title":"Differences among peritoneal and pleural mesothelioma: data from the Lombardy Region Mesothelioma Register (Italy)","volume":"102","author":"Mensi C","year":"2011","unstructured":"Mensi C, Bonzini M, Macchione M, et al. Differences among peritoneal and pleural mesothelioma: data from the Lombardy Region Mesothelioma Register (Italy). Med Lav 2011;102(5):409-16","journal-title":"Med Lav"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0b013e3283631cce"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000181"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3977-y"},{"issue":"7","key":"e_1_3_3_12_1","first-page":"718","article-title":"Latent period for malignant mesothelioma of occupational origin","volume":"34","author":"Lanphear BP","year":"1992","unstructured":"Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992;34(7):718-21","journal-title":"J Occup Med"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2012.03.001"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60251-6"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70257-2"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.19.2.3111"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/10937404.2011.556051"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgt166"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1006542107"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3481"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2013.07.029"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604008103"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04013-7"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4642"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.1002862"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1105887108"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000506"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.912"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e328302851d"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2007.10.054"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semtcvs.2009.06.008"},{"issue":"4","key":"e_1_3_3_32_1","first-page":"472","article-title":"Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma","volume":"1","author":"Friedberg JS","year":"2012","unstructured":"Friedberg JS. Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma. Ann Cardiothorac Surg 2012;1(4):472-80","journal-title":"Ann Cardiothorac Surg"},{"key":"e_1_3_3_33_1","article-title":"Real-time treatment light dose guidance of Pleural PDT: an update","author":"Zhu TC","year":"2015","unstructured":"Zhu TC, Kim MM, Jacques SL, et al. Real-time treatment light dose guidance of Pleural PDT: an update. Proc SPIE Int Soc Opt Eng 9308 2015. [Epub ahead of print]","journal-title":"Proc SPIE Int Soc Opt Eng 9308"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02303746"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2011.02.062"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2012.02.009"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2014.12.077"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2005.03.015"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20005.14.589"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc1039"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.09.003"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0301-3"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06816-7"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-179"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.910"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.10.015"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2011-100156"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2013.04.012"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2813"},{"key":"e_1_3_3_50_1","article-title":"A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma","author":"Wadt KA","year":"2014","unstructured":"Wadt KA, Aoude LG, Johansson P, et al. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin Genet 2014; Epub ahead of print","journal-title":"Clin Genet"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3459"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000471"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2012.02223.x"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1008"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000436"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-013-9677-2"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000250"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgu227"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201861"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0365"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08966"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01517-08"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.046755"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-011-9184-6"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00396-10"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3109"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1309085110"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0946"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2133"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.25.5.4539"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.12.074"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0901-3"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318194f991"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1579"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3765"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.14.167"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70056-2"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318191520c"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1221711"},{"key":"e_1_3_3_80_1","article-title":"Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma","author":"Napolitano A","year":"2015","unstructured":"Napolitano A, Pellegrini L, Dey A, et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 2015. [Epub ahead of print]","journal-title":"Oncogene"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106742"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2312"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.24.10854"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2375"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01578-08"},{"key":"e_1_3_3_86_1","unstructured":"S0722: Everolimus in treating patients with pleural malignant mesothelioma that cannot be removed by surgery. Available from: www.clinicaltrials.gov\/ct2\/show\/NCT00770120"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000360"},{"key":"e_1_3_3_88_1","unstructured":"Everolimus (RAD001) for the treatment of malignant pleural mesothelioma with Merlin\/NF2 loss as a biomarker to predict sensitivity. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01024946"},{"issue":"9","key":"e_1_3_3_89_1","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo A","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118(9):3065-74","journal-title":"J Clin Invest"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105919"},{"key":"e_1_3_3_91_1","unstructured":"A study of LY3023414 in participants with advanced cancer. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01655225"},{"key":"e_1_3_3_92_1","unstructured":"Phase I dose escalation study of VS-5584 in subjects with advanced non-hematologic malignancies or lymphoma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01991938"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.220"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1647"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209587"},{"key":"e_1_3_3_96_1","unstructured":"Study of a focal adhesion kinase inhibitor in subjects with solid tumors. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01138033"},{"key":"e_1_3_3_97_1","unstructured":"A dose escalation study to assess safety of GSK2256098 (FAK Inhibitor) in combination with trametinib (MEK Inhibitor) in subjects with advanced solid tumors. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01938443"},{"key":"e_1_3_3_98_1","unstructured":"Placebo controlled study of VS-6063 in subjects with malignant pleural mesothelioma (COMMAND). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01870609"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2010.09.011"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.08642"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgn200"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.5"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.192856.112"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0599"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/23.7.1127"},{"issue":"6","key":"e_1_3_3_106_1","first-page":"1227","article-title":"Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer","volume":"55","author":"Sekido Y","year":"1995","unstructured":"Sekido Y, Pass HI, Bader S, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995;55(6):1227-31","journal-title":"Cancer Res"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2006.04.011"},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018828"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/572609"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201870"},{"issue":"1","key":"e_1_3_3_111_1","first-page":"1","article-title":"Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide","volume":"28","author":"Frizelle SP","year":"2008","unstructured":"Frizelle SP, Kratzke MG, Carreon RR, et al. Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide. Anticancer research 2008;28(1A):1-7","journal-title":"Anticancer research"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318215a07d"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2559"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.2741\/3716"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.824"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1601"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.368"},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.05.111"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.5869"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.06.011"},{"key":"e_1_3_3_121_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318229586e"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182333df5"},{"key":"e_1_3_3_123_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31825f22ee"},{"key":"e_1_3_3_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-2008-6"},{"key":"e_1_3_3_125_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ec18db"},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31828c2b26"},{"key":"e_1_3_3_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2011.11.014"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1159\/000176386"},{"key":"e_1_3_3_129_1","doi-asserted-by":"publisher","DOI":"10.1159\/000087376"},{"issue":"11","key":"e_1_3_3_130_1","first-page":"2005","article-title":"Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors","volume":"6","author":"Versnel MA","year":"1991","unstructured":"Versnel MA, Claesson-Welsh L, Hammacher A, et al. Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene 1991;6(11):2005-11","journal-title":"Oncogene"},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-4781(95)00196-4"},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199602)178:2<151::AID-PATH425>3.0.CO;2-E"},{"key":"e_1_3_3_133_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0243-4"},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2005.04.010"},{"key":"e_1_3_3_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2013.12.008"},{"key":"e_1_3_3_136_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318248242c"},{"key":"e_1_3_3_137_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.7634"},{"key":"e_1_3_3_138_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1940"},{"key":"e_1_3_3_139_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23617"},{"issue":"5","key":"e_1_3_3_140_1","first-page":"1093","article-title":"Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis","volume":"18","author":"Strizzi L","year":"2001","unstructured":"Strizzi L, Vianale G, Catalano A, et al. Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int J Oncol 2001;18(5):1093-8","journal-title":"Int J Oncol"},{"key":"e_1_3_3_141_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201404-0658OC"},{"key":"e_1_3_3_142_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M414498200"},{"key":"e_1_3_3_143_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2003.tb01440.x"},{"key":"e_1_3_3_144_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389450116666141205160924"},{"key":"e_1_3_3_145_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1101"},{"key":"e_1_3_3_146_1","unstructured":"A clinical trial of ADI-PEG 20TM in patients with malignant pleural mesothelioma (ADAM). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01279967"},{"key":"e_1_3_3_147_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2005825"},{"key":"e_1_3_3_148_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20669"},{"key":"e_1_3_3_149_1","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2009-0060OC"},{"key":"e_1_3_3_150_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt412"},{"key":"e_1_3_3_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2011.04.008"},{"key":"e_1_3_3_152_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0536"},{"key":"e_1_3_3_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.05.008"},{"key":"e_1_3_3_154_1","doi-asserted-by":"publisher","DOI":"10.1177\/1947601911412375"},{"key":"e_1_3_3_155_1","unstructured":"ONCONASE plus doxorubicin versus doxorubicin alone for patients with malignant pleural or peritoneal mesothelioma who have had no more than one prior chemotherapy regimen. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00003034"},{"key":"e_1_3_3_156_1","volume-title":"Annual Report 2009","author":"Corporation A","year":"2009","unstructured":"Corporation A. Annual Report 2009. (Eds) 2009. Available from: www.alfacell.com\/annualreport2009.pdf"},{"key":"e_1_3_3_157_1","doi-asserted-by":"publisher","DOI":"10.1369\/jhc.5A6807.2006"},{"issue":"23","key":"e_1_3_3_158_1","first-page":"5334","article-title":"Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor","volume":"56","author":"Zanella CL","year":"1996","unstructured":"Zanella CL, Posada J, Tritton TR, Mossman BT. Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res 1996;56(23):5334-8","journal-title":"Cancer Res"},{"key":"e_1_3_3_159_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28218"},{"key":"e_1_3_3_160_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21160"},{"key":"e_1_3_3_161_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181839693"},{"key":"e_1_3_3_162_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21184"},{"key":"e_1_3_3_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"e_1_3_3_164_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_3_3_165_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000177"},{"key":"e_1_3_3_166_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121071"},{"key":"e_1_3_3_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70381-4"},{"key":"e_1_3_3_168_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00092-2"},{"key":"e_1_3_3_169_1","unstructured":"Randomized double-blind study comparing tremelimumab to placebo in subjects with unresectable malignant mesothelioma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01843374"},{"key":"e_1_3_3_170_1","unstructured":"Pembrolizumab in treating patients with malignant mesothelioma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02399371"},{"key":"e_1_3_3_171_1","unstructured":"Avelumab in metastatic or locally advanced solid tumors (JAVELIN Solid Tumor). Available from: www.clinicaltrials.gov\/ct2\/show\/NCT01772004"},{"key":"e_1_3_3_172_1","unstructured":"A potential immune therapy for mesothelioma. Cancer Discov 2015; Epub ahead of print"},{"key":"e_1_3_3_173_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26218"},{"key":"e_1_3_3_174_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0337"},{"key":"e_1_3_3_175_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2614"},{"key":"e_1_3_3_176_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M312372200"},{"key":"e_1_3_3_177_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-5-50"},{"key":"e_1_3_3_178_1","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Hassan R","year":"2007","unstructured":"Hassan R, Ebel W, Routhier EL, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 2007;7:20","journal-title":"Cancer Immun"},{"key":"e_1_3_3_179_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2009.07.016"},{"key":"e_1_3_3_180_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2275"},{"key":"e_1_3_3_181_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0804"},{"key":"e_1_3_3_182_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3980"},{"issue":"11","key":"e_1_3_3_183_1","first-page":"3520","article-title":"Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro","volume":"8","author":"Hassan R","year":"2002","unstructured":"Hassan R, Lerner MR, Benbrook D, et al. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res 2002;8(11):3520-6","journal-title":"Clin Cancer Res"},{"issue":"3","key":"e_1_3_3_184_1","first-page":"1327","article-title":"Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas","volume":"24","author":"Li Q","year":"2004","unstructured":"Li Q, Verschraegen CF, Mendoza J, Hassan R. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. Anticancer research 2004;24(3a):1327-35","journal-title":"Anticancer research"},{"key":"e_1_3_3_185_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0869"},{"key":"e_1_3_3_186_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0062"},{"key":"e_1_3_3_187_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28875"},{"key":"e_1_3_3_188_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006941"},{"key":"e_1_3_3_189_1","unstructured":"SS1P and pentostatin plus cyclophosphamide for mesothelioma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01362790"},{"key":"e_1_3_3_190_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0089-T"},{"key":"e_1_3_3_191_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0132"},{"key":"e_1_3_3_192_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1501958112"},{"key":"e_1_3_3_193_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0487-T"},{"key":"e_1_3_3_194_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0926"},{"key":"e_1_3_3_195_1","unstructured":"Phase I study to determine the maximum tolerable dose of BAY94-9343 in patients with advanced solid tumors. Available from: www.clinicaltrials.gov\/ct2\/show\/NCT01439152"},{"key":"e_1_3_3_196_1","unstructured":"A Phase I\/IIa study of BMS-986148 in subjects with select advanced solid tumors. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02341625"},{"key":"e_1_3_3_197_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081919"},{"key":"e_1_3_3_198_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-7-15"},{"key":"e_1_3_3_199_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2121"},{"key":"e_1_3_3_200_1","unstructured":"Safety and efficacy of listeria in combination with chemotherapy as front-line treatment for malignant pleural mesothelioma. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01675765"},{"key":"e_1_3_3_201_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.4244"},{"key":"e_1_3_3_202_1","unstructured":"GVAX pancreas vaccine (With CY) and CRS-207 with or without nivolumab. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02243371"},{"key":"e_1_3_3_203_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27983"},{"key":"e_1_3_3_204_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2880"},{"key":"e_1_3_3_205_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0351"},{"key":"e_1_3_3_206_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.256"},{"key":"e_1_3_3_207_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3874"},{"key":"e_1_3_3_208_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0170"},{"key":"e_1_3_3_209_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2627"},{"key":"e_1_3_3_210_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3010162"},{"key":"e_1_3_3_211_1","unstructured":"CART-meso in mesothelin expressing cancers. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02159716"},{"key":"e_1_3_3_212_1","unstructured":"CAR T cell receptor immunotherapy targeting mesothelin for patients with metastatic cancer. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01583686"},{"key":"e_1_3_3_213_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0708"},{"key":"e_1_3_3_214_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405884101"},{"key":"e_1_3_3_215_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0871-8"},{"key":"e_1_3_3_216_1","unstructured":"Vaccine therapy and GM-CSF in treating patients with acute myeloid leukemia myelodysplastic syndromes non-small cell lung cancer or mesothelioma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00398138"},{"key":"e_1_3_3_217_1","unstructured":"Randomized study of adjuvant WT-1 analog peptide vaccine in patients with malignant pleural mesothelioma (MPM) after completion of combined modality Therapy. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01265433"},{"key":"e_1_3_3_218_1","unstructured":"Phase II study of adjuvant WT-1 analog peptide vaccine in mpm patients after MSK10-134. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01890980"},{"issue":"12","key":"e_1_3_3_219_1","first-page":"5201","article-title":"Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor","volume":"32","author":"Tamanaka T","year":"2012","unstructured":"Tamanaka T, Oka Y, Fujiki F, et al. Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor. Anticancer Res 2012;32(12):5201-9","journal-title":"Anticancer Res"},{"key":"e_1_3_3_220_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056820"},{"key":"e_1_3_3_221_1","unstructured":"Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02408016"},{"key":"e_1_3_3_222_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.110"},{"key":"e_1_3_3_223_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-187"},{"key":"e_1_3_3_224_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0027"},{"key":"e_1_3_3_225_1","unstructured":"Re-directed T cells for the treatment (FAP)-positive malignant pleural mesothelioma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01722149"},{"key":"e_1_3_3_226_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0473"},{"key":"e_1_3_3_227_1","unstructured":"Tumor cell vaccines with ISCOMATRIX adjuvant and celecoxib in patients undergoing resection of lung and esophageal cancers and malignant pleural mesotheliomas. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01258868"},{"key":"e_1_3_3_228_1","unstructured":"Pilot study of allogeneic tumor cell vaccine with metronomic oral cyclophosphamide and celecoxib in patients undergoing resection of lung and esophageal cancers thymic neoplasms and malignant pleural mesotheliomas. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01143545"},{"key":"e_1_3_3_229_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28048"},{"key":"e_1_3_3_230_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1050572"},{"key":"e_1_3_3_231_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0628"},{"key":"e_1_3_3_232_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2004.03.010"},{"key":"e_1_3_3_233_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2013.1"},{"key":"e_1_3_3_234_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008095"},{"key":"e_1_3_3_235_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0216"},{"key":"e_1_3_3_236_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2010.10"},{"key":"e_1_3_3_237_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6265"},{"key":"e_1_3_3_238_1","unstructured":"Intrapleural measles virus therapy in patients with malignant pleural mesothelioma. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01503177"},{"key":"e_1_3_3_239_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3001"},{"key":"e_1_3_3_240_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2011.25"},{"key":"e_1_3_3_241_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.877"},{"key":"e_1_3_3_242_1","unstructured":"Intrapleural administration of HSV1716 to treat patients with malignant pleural mesothelioma. (1716-12). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01721018"},{"key":"e_1_3_3_243_1","unstructured":"Intrapleural gene transfer for pleural mesothelioma (IFN-alpha). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01212367"},{"key":"e_1_3_3_244_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2259"},{"key":"e_1_3_3_245_1","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2012.46"},{"key":"e_1_3_3_246_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0306164"},{"key":"e_1_3_3_247_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1953"},{"key":"e_1_3_3_248_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11710"},{"key":"e_1_3_3_249_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62110-1"},{"key":"e_1_3_3_250_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.153"},{"key":"e_1_3_3_251_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0306173"},{"key":"e_1_3_3_252_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200903124"},{"key":"e_1_3_3_253_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-205"},{"key":"e_1_3_3_254_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318297fa65"},{"key":"e_1_3_3_255_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318187491c"},{"key":"e_1_3_3_256_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6671"},{"key":"e_1_3_3_257_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051185"},{"key":"e_1_3_3_258_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1115050"},{"key":"e_1_3_3_259_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980130)75:3<362::AID-IJC6>3.0.CO;2-0"},{"key":"e_1_3_3_260_1","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0b013e32833c1bcb"},{"key":"e_1_3_3_261_1","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2012.649100"},{"key":"e_1_3_3_262_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.08.005"},{"key":"e_1_3_3_263_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103025"},{"key":"e_1_3_3_264_1","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-13-0244"}],"container-title":["Expert Review of Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/17476348.2015.1081066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:46:05Z","timestamp":1770417965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1586\/17476348.2015.1081066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,25]]},"references-count":260,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9,3]]}},"alternative-id":["10.1586\/17476348.2015.1081066"],"URL":"https:\/\/doi.org\/10.1586\/17476348.2015.1081066","relation":{},"ISSN":["1747-6348","1747-6356"],"issn-type":[{"value":"1747-6348","type":"print"},{"value":"1747-6356","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierx20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierx20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-08-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}